Richard S. Finn, MD, provides insight on the key risk factors that lead to hepatocellular carcinoma.
IMbrave150 for HCC
A review of prognostic factors and the importance of understanding underlying liver disease to help stage and treat patients with hepatocellular carcinoma.
Defining resectability in hepatocellular carcinoma based on burden of liver disease and Child-Pugh score.
Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.
Recent updates from the IMbrave150 study, which led to the FDA approval of frontline atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [HCC].
Efficacy, safety, and quality of life data from IMbrave150 have changed the standard of care for unresectable hepatocellular carcinoma.
Looking forward to further combinations and approaches for frontline and second-line therapy in advanced, unresectable hepatocellular carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
